Efficacy and Safety of Artemether in the Treatment of Chronic Fascioliasis in Egypt Exploratory Phase-2 Trials 英文参考文献.docVIP

下载本文档

3
0
约4.24万字
约 9页
2017-05-11 发布于上海
举报
版权申诉

Efficacy and Safety of Artemether in the Treatment of Chronic Fascioliasis in Egypt Exploratory Phase-2 Trials 英文参考文献.doc

1、本文档共9页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Efficacy and Safety of Artemether in the Treatment of Chronic Fascioliasis in Egypt Exploratory Phase-2 Trials 英文参考文献

EfficacyandSafetyofArtemetherintheTreatmentof ChronicFascioliasisinEgypt:ExploratoryPhase-2Trials JenniferKeiser1,2*,HananSayed3,MagedEl-Ghanam4,HodaSabry5,SaadAnani6,AlyEl-Wakeel7, ChristophHatz2,8,9,Ju¨rgUtzinger2,10,SayedSeifel-Din11,WalaaEl-Maadawy11,SanaaBotros11 1DepartmentofMedicalParasitologyandInfectionBiology,SwissTropicalandPublicHealthInstitute,Basel,Switzerland,2UniversityofBasel,Basel,Switzerland,3Public HealthDepartment,TheodorBilharzResearchInstitute,Giza,Egypt,4HepatogastroenterologyDepartment,TheodorBilharzResearchInstitute,Giza,Egypt,5Parasitology Department, TheodorBilharz ResearchInstitute,Giza, Egypt, 6Ministry ofHealth and Population, AlexandriaGovernorate,Alexandria, Egypt, 7Ministryof Health and Population,BeheraGovernorate,Behera,Egypt,8DepartmentofMedicalServicesandDiagnostic,SwissTropicalandPublicHealthInstitute,Basel,Switzerland,9Institute forSocialandPreventiveMedicine,UniversityofZurich,Zurich,Switzerland,10DepartmentofEpidemiologyandPublicHealth,SwissTropicalandPublicHealthInstitute, Basel,Switzerland,11PharmacologyDepartment,TheodorBilharzResearchInstitute,Giza,Egypt Abstract Background: Fascioliasis is an emerging zoonotic disease of considerable veterinary and public health importance. Triclabendazole is the only available drug for treatment. Laboratory studies have documented promising fasciocidal propertiesoftheartemisinins(e.g.,artemether). Methodology: We carried out two exploratory phase-2 trials to assess the efficacy and safety of oral artemether administeredat(i)6680mgover3consecutivedays,and(ii)36200mgwithin24hin36Fasciola-infectedindividualsin Egypt.Efficacywasdeterminedbycurerate(CR)andeggreductionrate(ERR)basedonmultipleKato-Katzthicksmears beforeandafter drugadministration.Patientswhoremained Fasciola-positivefollowingartemetherdosingweretreated withsingle10mg/kgoraltriclabendazole.Incaseoftreatmentfailure,triclabendazolewasre-administeredat20mg/kgin twodivideddoses. Principal Findings: CRs achieved with 6680mg a